U.S. markets open in 2 hours 57 minutes
  • S&P Futures

    3,788.50
    -1.00 (-0.03%)
     
  • Dow Futures

    30,764.00
    -17.00 (-0.06%)
     
  • Nasdaq Futures

    11,520.75
    -8.75 (-0.08%)
     
  • Russell 2000 Futures

    1,707.60
    -0.40 (-0.02%)
     
  • Crude Oil

    107.57
    +1.81 (+1.71%)
     
  • Gold

    1,791.00
    -16.30 (-0.90%)
     
  • Silver

    19.65
    -0.71 (-3.47%)
     
  • EUR/USD

    1.0476
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    2.9720
    0.0000 (0.00%)
     
  • Vix

    28.56
    +0.40 (+1.42%)
     
  • GBP/USD

    1.2086
    -0.0089 (-0.73%)
     
  • USD/JPY

    135.4310
    -0.2970 (-0.22%)
     
  • BTC-USD

    19,437.94
    +342.97 (+1.80%)
     
  • CMC Crypto 200

    418.41
    -13.06 (-3.03%)
     
  • FTSE 100

    7,198.01
    +28.73 (+0.40%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Post-split bluebird bio plans to launch 3 gene therapies in 2 years

·3 min read
Post-split bluebird bio plans to launch 3 gene therapies in 2 years
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Following the spinout of its cancer business, bluebird bio Inc. is all in on gene therapy, with plans to launch three new drugs by the end of 2023.